OLMA — Olema Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $335.52m
- -$98.57m
- 34
- 37
- 45
- 32
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.82 | ||
| Price to Tang. Book | 0.82 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -34.76% | ||
| Return on Equity | -39.07% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 3.75 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
Directors
- Ian Clark NEC (60)
- Sean Bohen PRE (54)
- Shane Kovacs CFO (47)
- John Moriarty EVP (53)
- Cyrus Harmon CTO (50)
- Peter Kushner CSO (82)
- Kinney Horn OTH (46)
- David Myles OTH (58)
- Naseem Zojwalla OTH
- Cynthia Butitta IND (66)
- Sandra Horning IND (72)
- Gorjan Hrustanovic IND (32)
- Yi Larson IND (41)
- Andrew Rappapor IND (63)
- Graham Walmsley IND (34)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 7th, 2006
- Public Since
- November 19th, 2020
- No. of Shareholders
- 67
- No. of Employees
- 96
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 68,333,065
- Address
- 780 Brannan Street, SAN FRANCISCO, 94103
- Web
- https://olema.com/
- Phone
- +1 4156513316
- Auditors
- Ernst & Young LLP
Upcoming Events for OLMA
Olema Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Olema Pharmaceuticals Inc Earnings Release
Similar to OLMA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Olema Pharmaceuticals share price?
As of Today at 22:25 UTC, shares in Olema Pharmaceuticals are trading at $4.91. This share price information is delayed by 15 minutes.
How has the Olema Pharmaceuticals share price performed this year?
Shares in Olema Pharmaceuticals last closed at $4.91 and the price had moved by -50.05% over the past 365 days. In terms of relative price strength the Olema Pharmaceuticals share price has underperformed the S&P500 Index by -53.9% over the past year.
What are the analyst and broker recommendations for Olema Pharmaceuticals?
The overall consensus recommendation for Olema Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Olema Pharmaceuticals dividend yield?
Olema Pharmaceuticals does not currently pay a dividend.
Does Olema Pharmaceuticals pay a dividend?
Olema Pharmaceuticals does not currently pay a dividend.
When does Olema Pharmaceuticals next pay dividends?
Olema Pharmaceuticals does not currently pay a dividend.
How do I buy Olema Pharmaceuticals shares?
To buy shares in Olema Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Olema Pharmaceuticals?
As of the previous close price of $4.91, shares in Olema Pharmaceuticals had a market capitalisation of $335.52m.
Where are Olema Pharmaceuticals shares listed?
Here are the trading details for Olema Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: OLMA
What kind of share is Olema Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Olema Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Olema Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Olema Pharmaceuticals is $26.40. That is 437.68% above the last closing price of $4.91.
Analysts covering Olema Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$2.33 for the next financial year.
Find out moreWhat is the trend in the Olema Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Olema Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -55.19%.
As of the last closing price of $4.91, shares in Olema Pharmaceuticals were trading -44.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Olema Pharmaceuticals PE Ratio?
The Olema Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.91.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Olema Pharmaceuticals?
Olema Pharmaceuticals' management team is headed by:
- Ian Clark - NEC
- Sean Bohen - PRE
- Shane Kovacs - CFO
- John Moriarty - EVP
- Cyrus Harmon - CTO
- Peter Kushner - CSO
- Kinney Horn - OTH
- David Myles - OTH
- Naseem Zojwalla - OTH
- Cynthia Butitta - IND
- Sandra Horning - IND
- Gorjan Hrustanovic - IND
- Yi Larson - IND
- Andrew Rappapor - IND
- Graham Walmsley - IND